Address: National Institute for Health Research,Room 132,Richmond House, 79 Whitehall, London,SW1A 2NS
Tel: +44(0)20 7270 5251
Web: http://www.nihr.ac.uk/about/Pages/about_oschr.aspx
OSCHR was jointly set up as a Government office in January 2007 by the Department of Heath in England (DH) and the Department for Business, Innovation and Skills (BIS).
The UK Government currently funds health related research through two main routes, the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). On 31 March 2006, Sir David Cooksey was appointed to lead a review to build agreement on the best institutional arrangements for the new single fund for health research. A copy of the report can be downloaded from the Treasury website.
The review concluded that, although good progress has been made in some areas, further work is needed to ensure that publicly funded health research is carried out in the most effective and efficient way, and to facilitate rapid translation of research findings into health and economic benefits. The report recommended specific actions which Government can take to achieve this. In his Pre-Budget Report on 6 December 2006, the Chancellor announced that he and the Secretaries of State for Health and for Trade and Industry (now Department for Business Innovation and Skills) welcomed the report and would work to take forward its recommendations.
A key recommendation of the review was the establishment of a new Office for Strategic Coordination of Health Research (OSCHR) that will take an overview of the budgetary division and research strategy of both the MRC and NIHR.
OSCHR’s mission is to facilitate more efficient translation of health research into health and economic benefits in the UK through better coordination of health research and more coherent funding arrangements to support translation.
OSCHR has responsibility for:
x Translational Medicine Research
x Public Health Research
x E-Health Records Research
x Methodology Research
x Human Capital
Three Boards – a Translational Medicine Board (TMB), an E-Health Records Research Board (EHRRB) and a Public Health Research Board (PHRB) – have been established to provide strategic oversight in these areas. These Boards do not have a direct funding role.
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals…
AstraZeneca has made a bold move by offering its in-house digital clinical trial expertise to clinical research organisations (CROs) and other pharmaceutical companies via the launch of healthtech business Evinova.…
Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid…
Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Several macro-trends affected the pharmaceutical industry in 2022, impacting its inventory position, writes Matthew Bardell, managing director of specialist inventory consultants nVentic. Bardell highlights findings in a recent report –…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs…
See our Cookie Privacy Policy Here
